Edition:
United States

Profile: Allergan plc (AGN)

AGN on New York Consolidated

248.98USD
22 Jul 2016
Change (% chg)

$1.14 (+0.46%)
Prev Close
$247.84
Open
$248.50
Day's High
$249.75
Day's Low
$247.78
Volume
1,962,936
Avg. Vol
4,671,549
52-wk High
$340.34
52-wk Low
$195.50

Allergan plc, formerly Actavis plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products (brand, branded or specialty brand), medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through four segments: US Brands, US Medical Aesthetics, International Brands and Anda Distribution. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States. The Anda Distribution segment includes distribution of generic and branded pharmaceutical products manufactured by third parties, as well as by the Company.

In its US Brands, US Medical Aesthetics and International Brands operations, the Company sells its brand pharmaceutical products to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies and managed healthcare providers, such as health maintenance organizations and other institutions. In its Anda Distribution business, the Company distributes brand pharmaceutical products to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains, physicians' offices and buying groups.

The Company is developing a range of branded products, some of which utilize drug delivery systems, through a combination of internal and collaborative programs, including Restasis MDPF, XEN45, Sarecycline, Esmya, Bimatoprost SR, Tavilermide, Relamorelin, Ubrogepant, Abicipar and Rapastinel. The Company's portfolio of branded pharmaceutical products within the US Brands segment includes Alphagan/Combigan, which is used for the treatment of selective alpha2 agonist; Asacol/Delzicol, which is used for the treatment of ulcerative colitis; Botox, which is used for the treatment of acetylcholine release inhibitor; Bystolic, which is used for the treatment of hypertension; Carafate/Sulcrate, which is used for the treatment of ulcerative colitis; Dalvance, which is used for the treatment of acute bacterial skin infections; Estrace Cream, which is used for the treatment of hormone therapy; Linzess/Constella, which is used for the treatment of irritable bowel syndrome; Lo Loestrin Fe, which is used for the treatment of oral contraceptive; Lumigan/Ganfort, which is used for the treatment of prostaglandin analogue; Minastrin 24 Fe, which is used for the treatment of oral contraceptive; Namenda XR and Namzaric, which are used for the treatment of Dementia; Restasis, which is used for the treatment of topical immunomodulator; Saphris, which is used for the treatment of schizophrenia, bipolar mania; Teflaro, which is used for the treatment of acute bacterial skin infections, community-acquired bacterial pneumonia; Viberzi, which is used for the treatment of irritable bowel syndrome; Viibryd/Fetzima, which is used for the treatment of depressive disorders, and Zenpep, which is used for the treatment of exocrine pancreatic insufficiency.

The Company's US Medical Aesthetics segment offers a range of silicone gel and saline breast implant options, as well as a science-based facial aesthetic portfolio. Its portfolio of products within the US Medical Aesthetics segment includes Aczone, which is used for the treatment of acne; Botox, which is used as musculoskeletal agent; Breast Implants, which is a reconstructive plastic surger, and Juvederm/Voluma, which is used for the treatment of nasolabial folds. The Company's International Brands segment offers a range of branded and aesthetics products outside of the United States. Its portfolio of products within the International Brands segment includes Alphagan/Combigan, Breast Implants, Botox, Juvederm/Voluma and Lumigan/Ganfort.

The Company competes with McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc.

Company Address

Allergan plc

Clonshaugh Business And Technolo
Coolock
DUBLIN     D17 E400
P: +35321.65235000

Company Web Links